These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39100523)

  • 1. Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle?
    Crapis M; Venturini S; Callegari A; Del Fabro G; Bramuzzo I; De Santi L; Pontoni E; Tonizzo M; Basso B
    Glob Reg Health Technol Assess; 2024; 11(Suppl 2):18-21. PubMed ID: 39100523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
    Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
    Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
    Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
    Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
    Oliva A; Carbonara S; Cianci V; Crapis M; Di Domenico EG; Falcone M; Galardo G; Durante-Mangoni E; Venditti M
    Expert Rev Anti Infect Ther; 2023; 21(7):703-721. PubMed ID: 37227028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
    LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
    J Emerg Med; 2024 Aug; 67(2):e217-e229. PubMed ID: 38825531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
    Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
    Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
    Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI.
    Carbonara S
    Glob Reg Health Technol Assess; 2024; 11(Suppl 2):13-17. PubMed ID: 39100524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
    Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
    J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 14. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
    Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
    Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
    Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
    Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries.
    Marcellusi A; Viti R; Sciattella P; Sarmati L; Streinu-Cercel A; Pana A; Espin J; Horcajada JP; Favato G; Andretta D; Soro M; Andreoni M; Mennini FS
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):581-599. PubMed ID: 30714834
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
    Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
    Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
    Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Sep; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
    Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.